Future research should focus on precision anti-inflammatory/antioxidant therapies targeting CKD-MBD, such as combined strategies targeting RANK or the Nrf2 pathway, while strictly evaluating their long-term impacts on mineral metabolism. The gene discussed is TNFRSF11A; the disease is Marchiafava-Bignami disease.